Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
On October 24, 2024, the Company and Yoov Group Holding Limited ("Yoov") entered into a termination agreement and the anticipated reverse takeover transaction with Yoov was terminated.NEW YORK--(BUSINESS WIRE)--Dec. 20, 2024--Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024.
紐約--（商業通訊）--2024年12月20日--知臨集團有限公司（納斯達克：APM）（"知臨集團"或"公司"），是一家臨牀階段的生物製藥公司，致力於滿足腫瘤、自身免疫和傳染病領域未滿足的醫療需求，今天提供了業務更新並公佈了截至2024年6月30日的六個月財務業績。
"Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary transactional and listing documentation. However, current market conditions have introduced significant uncertainty regarding the availability of the required funding for the transaction. After careful consideration, our Board has determined that it is no longer in the best interests of our shareholders to proceed with this transaction. Despite this, we will continue to explore other business combination opportunities that we believe will enhance shareholder value," stated Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group Limited.
"我們的團隊與Yoov花費了大量時間和精力進行盡職調查、談判最終條款以及準備必要的交易和上市文件。然而，當前的市場控制項帶來了關於交易所需資金可用性的重大不確定性。經過仔細考慮，我們的董事會已決定繼續進行此交易不再符合我們股東的最佳利益。儘管如此，我們將繼續探索其他我們認爲將提升股東價值的業務組合機會，"知臨集團有限公司的首席執行官兼執行董事Ian Huen先生表示。
Corporate Highlights
公司亮點
On October 24, 2024, the Company and Yoov Group Holding Limited ("Yoov") entered into a termination agreement and the anticipated reverse takeover transaction with Yoov was terminated.
2024年10月24日，公司與Yoov集團控股有限公司（"Yoov"）簽署了一項終止協議，與Yoov的預期反向收購交易被終止。
Financial Results for the Six Months Ended June 30, 2024
截至2024年6月30日的六個月財務業績
Aptorum Group reported a net loss of $2.7 million for the six months ended June 30, 2024 compared to $6.6 million for the same period in 2023. The decrease in net loss in the current period was driven by the decrease in operating expenses by $4.1 million due to the implementation of stringent budgetary control measures, as a result of the Company's exclusive emphasis on the previous anticipated RTO.
知臨集團報告截至2024年6月30日的六個月淨虧損爲270萬，而2023年同期爲660萬。本期淨虧損的下降是由於公司嚴格實施預算控制措施，營業費用減少了410萬，因公司特定專注於之前預期的反向收購。
Research and development expenses were $2.0 million for the six months ended June 30, 2024 compared to $3.2 million for the same period in 2023. Before the Merger Agreement was terminated, we determined it was best to focus all of our attention and resources on completing the Merger and therefore paused the majority of our R&D activities during that time; following the termination of the Merger Agreement in the fourth quarter of fiscal 2024, we determined that searching for other business combination opportunities could maximize shareholder value, and our R&D activities remain suspended.
截至2024年6月30日的六個月研發費用爲200萬，而2023年同期爲320萬。在合併協議終止之前，我們確定最好的方式是將所有注意力和資源集中在完成合並上，因此在此期間暫停了大部分研發活動；在2024財政年度第四季度合併協議終止後，我們決定尋找其他業務組合機會可能會最大化股東價值，我們的研發活動仍然處於暫停狀態。
General and administrative fees were $0.3 million for the six months ended June 30, 2024 compared to $1.3 million for the same period in 2023. The decrease in general and administrative fees was primary due to the streamlining of our operations to focus on preparation for the Merger, which has since been abandoned.
截止到2024年6月30日的六個月內，一般和行政費用爲30萬美元，相比之下，2023年同一時期的費用爲130萬美元。一般和行政費用的減少主要是由於我們對運營進行了精簡，專注於合併的準備工作，但該合併已被放棄。
Legal and professional fees were $0.4 million for the six months ended June 30, 2024 compared to $1.7 million for the same period in 2023. The decrease in legal and professional fees was attributed to the lack of non-routine activities that were present in the same period last year, such as the implementation of reverse stock split, and amendments to the memorandum and articles of association. The absence of such non-routine exercises in the current period has resulted in a decrease in legal and professional fees.
截止到2024年6月30日的六個月內，法律和專業費用爲40萬美元，相比之下，2023年同一時期的費用爲170萬美元。法律和專業費用的減少歸因於缺乏去年同期存在的非例行活動，例如實施反向股票拆分和對章程及細則的修訂。在目前期間缺乏此類非例行活動，導致法律和專業費用的減少。
As of June 30, 2024, cash and restricted cash totaled approximately $0.8 million and total equity was approximately $13.2 million.
截至2024年6月30日，現金和受限現金總計約80萬美元，總權益約爲1320萬美元。
|
APTORUM GROUP LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2024 and December 31, 2023 (Stated in U.S. Dollars) | ||||||||
June 30, |
December 31, |
|||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash |
$ |
783,085 |
$ |
2,005,351 |
||||
Accounts receivable |
21,800 |
47,709 |
||||||
Amounts due from related parties |
3,595 |
961 |
||||||
Other receivables and prepayments |
725,616 |
422,071 |
||||||
Total current assets |
1,534,096 |
2,476,092 |
||||||
Property and equipment, net |
- |
1,663,926 |
||||||
Operating lease right-of-use assets |
- |
182,057 |
||||||
Long-term investments |
16,098,846 |
16,098,846 |
||||||
Intangible assets, net |
- |
147,347 |
||||||
Long-term deposits |
71,823 |
71,823 |
||||||
Total Assets |
$ |
17,704,765 |
$ |
20,640,091 |
||||
LIABILITIES AND EQUITY |
||||||||
LIABILITIES |
||||||||
Current liabilities: |
||||||||
Amounts due to related parties |
$ |
79,180 |
$ |
79,180 |
||||
Accounts payable and accrued expenses |
1,148,235 |
1,894,341 |
||||||
Operating lease liabilities, current |
89,145 |
125,232 |
||||||
Total current liabilities |
1,316,560 |
2,098,753 |
||||||
Operating lease liabilities, non-current |
62,718 |
99,485 |
||||||
Convertible notes to a related party |
3,148,500 |
3,058,500 |
||||||
Total Liabilities |
$ |
4,527,778 |
$ |
5,256,738 |
||||
Commitments and contingencies |
- |
- |
||||||
EQUITY |
||||||||
Class A Ordinary Shares ($0.00001 par value, 9,999,996,000,000 shares authorized, 3,674,164 shares issued and outstanding as of June 30, 2024; 2,937,921 shares issued and outstanding as of December 31, 2023) |
$ |
37 |
$ |
31 |
||||
Class B Ordinary Shares ($0.00001 par value; 4,000,000 shares authorized, 1,796,934 shares issued and outstanding as of June 30, 2024; 2,243,776 shares issued and outstanding as of December 31, 2023) |
18 |
22 |
||||||
Additional paid-in capital |
93,470,186 |
93,018,528 |
||||||
Accumulated other comprehensive loss |
(9,762) |
(10,623) |
||||||
Accumulated deficit |
(70,805,518) |
(68,161,722) |
||||||
Total equity attributable to the shareholders of Aptorum Group Limited |
22,654,961 |
24,846,236 |
||||||
Non-controlling interests |
(9,477,974) |
(9,462,883) |
||||||
Total equity |
13,176,987 |
15,383,353 |
||||||
Total Liabilities and Equity |
$ |
17,704,765 |
$ |
20,640,091 |
||||
|
知臨集團有限公司 未經審計的合併資產負債表 2024年6月30日和2023年12月31日 (以美元計) | ||||||||
6月30日 |
12月31日 |
|||||||
資產 |
||||||||
流動資產： |
||||||||
現金 |
$ |
783,085 |
$ |
2,005,351 |
||||
應收賬款 |
21,800 |
47,709 |
||||||
應收關聯方款項 |
3,595 |
961 |
||||||
其他應收款和預付款 |
725,616 |
422,071 |
||||||
總流動資產 |
1,534,096 |
2,476,092 |
||||||
物業及設備（淨額） |
- |
1,663,926 |
||||||
經營租賃使用權資產 |
- |
182,057 |
||||||
長期投資 |
16,098,846 |
16,098,846 |
||||||
無形資產，淨值 |
- |
147,347 |
||||||
長期存款 |
71,823 |
71,823 |
||||||
總資產 |
$ |
17,704,765 |
$ |
20,640,091 |
||||
負債和權益 |
||||||||
負債 |
||||||||
流動負債： |
||||||||
應付相關方款項 |
$ |
79,180 |
$ |
79,180 |
||||
應付賬款和預提費用 |
1,148,235 |
1,894,341 |
||||||
經營租賃負債，流動 |
89,145 |
125,232 |
||||||
總流動負債 |
1,316,560 |
2,098,753 |
||||||
經營租賃負債，非流動 |
62,718 |
99,485 |
||||||
可轉換票據給關聯方 |
3,148,500 |
3,058,500 |
||||||
總負債 |
$ |
4,527,778 |
$ |
5,256,738 |
||||
承諾與或有事項 |
- |
- |
||||||
股本 |
||||||||
A類普通股（面值$0.00001，授權發行9,999,996,000,000股，截至2024年6月30日已發行並流通3,674,164股；截至2023年12月31日已發行並流通2,937,921股） |
$ |
37 |
$ |
31 |
||||
B類普通股（面值$0.00001；授權數量4,000,000股，截至2024年6月30日已發行並流通1,796,934股；截至2023年12月31日已發行並流通2,243,776股） |
18 |
22 |
||||||
額外實收資本 |
93,470,186 |
93,018,528 |
||||||
累計其他綜合損失 |
(9,762) |
(10,623) |
||||||
累計虧損 |
(70,805,518) |
(68,161,722) |
||||||
歸屬於知臨集團股東的總權益 |
22,654,961 |
24,846,236 |
||||||
非控股權益 |
(9,477,974) |
(9,462,883) |
||||||
總權益 |
13,176,987 |
15,383,353 |
||||||
總負債和權益 |
$ |
17,704,765 |
$ |
20,640,091 |
||||
|
APTORUM GROUP LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the six months ended June 30, 2024 and 2023 (Stated in U.S. Dollars) | ||||||||
For the six months ended |
||||||||
2024 |
2023 |
|||||||
Revenue |
||||||||
Healthcare services income |
$ |
- |
$ |
431,378 |
||||
Operating expenses |
||||||||
Costs of healthcare services |
- |
(426,063) |
||||||
Research and development expenses |
(2,038,923) |
(3,212,366) |
||||||
General and administrative fees |
(326,187) |
(1,263,019) |
||||||
Legal and professional fees |
(366,164) |
(1,738,566) |
||||||
Other operating expenses |
(137,233) |
(330,212) |
||||||
Total operating expenses |
(2,868,507) |
(6,970,226) |
||||||
Other income (expenses) |
||||||||
Loss on investments in marketable securities, net |
- |
(9,266) |
||||||
Interest expense, net |
(68,462) |
(93,478) |
||||||
Loss on disposal of subsidiaries |
(4,271) |
- |
||||||
Sundry income |
282,353 |
36,803 |
||||||
Total other income (expenses), net |
209,620 |
(65,941) |
||||||
Net loss |
$ |
(2,658,887) |
$ |
(6,604,789) |
||||
Less: net loss attributable to non-controlling interests |
(15,091) |
(1,117,685) |
||||||
Net loss attributable to Aptorum Group Limited |
$ |
(2,643,796) |
$ |
(5,487,104) |
||||
Net loss per share – basic and diluted |
$ |
(0.50) |
$ |
(1.43) |
||||
Weighted-average shares outstanding – basic and diluted |
5,339,608 |
3,849,621 |
||||||
Net loss |
$ |
(2,658,887) |
$ |
(6,604,789) |
||||
Other comprehensive income (loss) |
||||||||
Exchange differences on translation of foreign operations |
861 |
(7,485) |
||||||
Other comprehensive income (loss) |
861 |
(7,485) |
||||||
Comprehensive loss |
(2,658,026) |
(6,612,274) |
||||||
Less: comprehensive loss attributable to non-controlling interests |
(15,091) |
(1,117,685) |
||||||
Comprehensive loss attributable to the shareholders of Aptorum Group Limited |
(2,642,935) |
(5,494,589) |
||||||
|
知臨集團有限公司 未經審計的簡明合併運營和綜合虧損報表 截至2024年和2023年6月30日的六個月 (以美元計) | ||||||||
截至六個月 |
||||||||
2024 |
2023 |
|||||||
營業收入 |
||||||||
醫療服務收入 |
$ |
- |
$ |
431,378 |
||||
營業費用 |
||||||||
醫療服務成本 |
- |
(426,063) |
||||||
研發費用 |
(2,038,923) |
(3,212,366) |
||||||
一般和行政費用 |
(326,187) |
(1,263,019) |
||||||
法律和專業費用 |
(366,164) |
(1,738,566) |
||||||
其他營業費用 |
(137,233) |
(330,212) |
||||||
總營業費用 |
(2,868,507) |
(6,970,226) |
||||||
其他收入（費用） |
||||||||
可交易證券的投資損失，淨額 |
- |
(9,266) |
||||||
利息費用，淨額 |
(68,462) |
(93,478) |
||||||
處置子公司的損失 |
(4,271) |
- |
||||||
雜項收入 |
282,353 |
36,803 |
||||||
其他淨收入（費用）總額 |
209,620 |
(65,941) |
||||||
淨損失 |
$ |
(2,658,887) |
$ |
(6,604,789) |
||||
Less: net loss attributable to non-controlling interests |
(15,091) |
(1,117,685) |
||||||
歸屬於知臨集團的淨虧損 |
$ |
(2,643,796) |
$ |
(5,487,104) |
||||
每股淨虧損 - 基本和攤薄 |
$ |
(0.50) |
$ |
(1.43) |
||||
加權平均基本及稀釋後流通股數 |
5,339,608 |
3,849,621 |
||||||
淨損失 |
$ |
(2,658,887) |
$ |
(6,604,789) |
||||
其他綜合收益（損失） |
||||||||
外幣報表折算差額 |
861 |
(7,485) |
||||||
其他綜合收益（損失） |
861 |
(7,485) |
||||||
綜合損失 |
(2,658,026) |
(6,612,274) |
||||||
減：歸屬於非控股權益的綜合損失 |
(15,091) |
(1,117,685) |
||||||
歸屬於知臨集團股東的綜合損失 |
(2,642,935) |
(5,494,589) |
||||||
About Aptorum Group
關於知臨集團
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.
知臨集團有限公司（納斯達克：APM）是一家臨牀階段的生物製藥公司，致力於發現、開發和商業化治療未滿足醫療需求的疾病的治療資產，特別是在腫瘤學（包括孤兒腫瘤指徵）和傳染病方面。知臨集團的產品線還通過與新加坡科學技術與研究局的商業化部門Accelerate Technologies Pte Ltd共同開發PathsDx Test，增強了該公司在快速病原體識別和檢測診斷技術方面的能力。
For more information about the Company, please visit .
有關公司的更多信息，請訪問。
Disclaimer and Forward-Looking Statements
免責聲明和前瞻性聲明
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.
本新聞稿不構成向出售或請求購買知臨集團任何證券的要約。
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations.
本新聞稿包含有關知臨集團有限公司及其未來期望、計劃和前景的聲明，這構成了1995年美國私人證券訴訟改革法案意義上的「前瞻性聲明」。爲此，本文中包含的任何不爲歷史事實的陳述可視爲前瞻性聲明。在某些情況下，您可以通過諸如「可能」、「應該」、「期望」、「計劃」、「預測」、「能夠」、「打算」、「目標」、「項目」、「考慮」、「相信」、「估計」、「預測」、「潛力」或「繼續」等術語或這些術語的否定形式或其他類似表達來識別前瞻性聲明。知臨集團基於這些前瞻性聲明，其包括針對申請提交和試驗的預計時間表的聲明，主要基於其對未來事件和趨勢的當前期望和預測，這些可能影響其業務、財務狀況和運營結果。
These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein.
這些前瞻性聲明僅在本新聞稿發佈日期有效，並且受到諸多風險、不確定性和假設的限制，包括但不限於與其已公佈的管理和組織變更相關的風險、關鍵人員的持續服務和可用性、通過爲其他消費群體提供額外產品而擴展產品品類的能力、開發結果、公司的預期增長戰略、業務中的預期趨勢和挑戰，以及公司對其供應鏈的期望及穩定性，以及在知臨集團的20-F表格和知臨集團未來可能向SEC提交的其他文檔中更全面描述的風險。因此，包含在這些前瞻性聲明中的預測可能會發生變化，實際結果可能與此處描述的顯著不同。
Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
知臨集團沒有義務因新信息、未來事件或其他原因更新本新聞稿中包含的任何前瞻性聲明。
This press release is provided "as is" without any representation or warranty of any kind.
本新聞稿以 "原樣" 提供，不作任何形式的陳述或保證。
View source version on businesswire.com:
在businesswire.com查看源版本：
Aptorum Group Limited
Investor Relations Department
investor.relations@aptorumgroup.com
+44 20 80929299
知臨集團有限公司
投資者關係部
investor.relations@aptorumgroup.com
+44 20 80929299
Source: Aptorum Group Limited
來源：知臨集團有限公司
譯文內容由第三人軟體翻譯。
